This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Journal and News Scan
A study, published on June 9 in the Journal of Cardiac Failure, shows heart failure patients who are unvaccinated against COVID-19 are three times more likely to die if infected with the virus compared to fully vaccinated and boosted heart failure patients. The study's corresponding author Anurhada Lala, MD, Director of Heart Failure Research and an Associate Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai, said in a press release that these findings can be useful to help educate reluctant patients and encourage them to follow through with full vaccination, including boosters, with the goal of improving their chances of survival.
In September 2015, the United Nations introduced Sustainable Development Goals (SDGs) to address persistent gaps in global health by 2030. Of the seventeen SDGs, the authors posit how fifteen goals can be directly or indirectly influenced by the cardiothoracic community. Amid the growing movement of National Surgical, Obstetric, and Anesthesia Plans developed by dozens of countries worldwide and catalyzed by local Ministries of Health and the World Health Organization, cardiac surgery receives little mention because of a lack of individual and societal voices at the table. The cardiothoracic community, however, is ideally positioned to play a pivotal role in securing future access to quality global cardiovascular care.
No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question....
This is a compreshensive review on the experience with use of TEVAR in patients with Marfan syndrome, including durablity, complications, and timing, etc. Drs. Steinmetz and Cosellihe also discussed the role and trend of TEVAR in Marfan paitents with aortic disease.
Transcatheter aortic valve replacement (TAVR) is not inferior to surgical aortic valve replacement (SAVR) when it comes to all-cause mortality after one year. This is among moderate-risk patients with severe, symptomatic aortic stenosis (AS). According to a new analysis published in JAMA, a close comparison revealed that each treatment option is associated with certain benefits over the other.